evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

634 questions · 675 findings · 72 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 155 · 23%GRADE not reported 50 · 7.4%Very low 144 · 21.3%Low 166 · 24.6%Moderate 119 · 17.6%High 41 · 6.1%

High‐intensity vs low‐intensity exercise programmes

Functional ability · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)

It is very uncertain whether high‐intensity changes functional ability (short‐term) FIQ modified (0 to 16; higher scores… compared with low‐intensity exercise programmes (very low certainty).

2 findings from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Anuria · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in anuria compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Non‐fatal cardiovascular events · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular events (non‐fatal) compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Cough · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in cough compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Hyperkalaemia · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in hyperkalaemia compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Death (all causes) · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Cardiovascular mortality · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Doubling of SCr Median · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review